Abstracts tagged "Juvenile Arthritis"

Abstract Number: 2018 • 2017 ACR/ARHP Annual Meeting
A Novel Ultrasound Scoring System for the Pediatric Knee
Tracy Ting¹, Patricia Vega-Fernandez², Edward Oberle³, Deirdre De Ranieri⁴, Hulya Bukulmez⁵ and Johannes Roth⁶, ¹Rheumatology/MLC 4010, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Pediatric Rheumatology, The University of Chicago Medicine, Chicago, IL, ⁵Pediatric Rheumatology, MetroHealth Medical Center, Cleveland, OH, ⁶Pediatric Rheumatology, Children's Hospital Eastern Ontario, Ottawa, ON, Canada
Background/Purpose: Musculoskeletal ultrasound (MSUS) is increasingly being utilized in children. In order to provide objective assessments of arthritis, reliable scoring systems are needed. Yet, given…
Abstract Number: 2281 • 2017 ACR/ARHP Annual Meeting
Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry
Sarah Ringold¹, Fenglong Xie², Daniel B. Horton³, Melissa L. Mannion⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Seattle Children's Hospital, Seattle, WA, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry began enrolling children with juvenile idiopathic arthritis (JIA) in July 2015. The large number of…
Abstract Number: 2282 • 2017 ACR/ARHP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Katherine Murphy⁹ and Yukiko Kimura⁶, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Parent Partner, San Francisco, CA
Background/Purpose: Despite the many available new and effective treatments for polyarticular JIA (P-JIA), there is significant variation in the timing of when biologic medications are…
Abstract Number: 2289 • 2017 ACR/ARHP Annual Meeting
Individualized Prediction of Early Remission on Medication in Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Kiem Oen³, Natalie J. Shiff⁴, Roberta Berard⁵, Roman Jurencak⁶, Adam Huber⁷, Kerstin Gerhold⁸, Susanne Benseler⁹, Ciarán M. Duffy¹⁰ and Lori Tucker¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Department of Pediatrics and Child Health University of Manitoba, Winnipeg, MB, Canada, ⁴University of Florida, Gainesville, FL, ⁵Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸Pediatrics, University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes cohort (ReACCh-Out) showed a 45% chance of attaining inactive disease within a year of…
Abstract Number: 38 • 2017 Pediatric Rheumatology Symposium
Knowledge Translation in Juvenile Idiopathic Arthritis Research in Canada: A Focus on Pediatric Rheumatologists and Allied Health Professionals
Benjamin Rose-Davis¹, Janet Curran², Tania Cellucci³, Ciarán M. Duffy⁴, Lori Tucker^5,6, Michelle Batthish⁷, Adam Huber⁸, Bianca Lang^9,10, Deborah M. Levy¹¹, Dax Rumsey¹², Karen N Watanabe Duffy¹³ and Elizabeth Stringer¹⁴, ¹Division of Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²Department of Pediatrics, IWK Health Centre, Halifax, NS, Canada, ³Pediatrics/Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ⁴Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁵Rheumatology, BC Childrens Hospital, Vancouver, BC, Canada, ⁶Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ⁷Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ⁸IWK Health Centre, Halifax, NS, Canada, ⁹Pediatrics, IWK Health Centre, Halifax, NS, Canada, ¹⁰Rheumatology, IWK Health Centre, Halifax, NS, Canada, ¹¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹²Stollery Children's Hospital, Edmonton, AB, Canada, ¹³Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹⁴Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada
Background/Purpose: Knowledge Translation (KT) is an iterative process that includes synthesis, dissemination, and application of knowledge to improve health. The aim of this study is…
Abstract Number: 58 • 2017 Pediatric Rheumatology Symposium
Analysis and Implications of Non-Invasive Knee Acoustical Emissions in Juvenile Idiopathic Arthritis
Daniel Whittingslow^1,2, Beren Semiz³, Lori Ponders⁴, Andrew Wiens⁵, Omer Inan^3,6 and Sampath Prahalad⁷, ¹Emory University School of Medicine, Atlanta, GA, ²Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ³Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Computer Science, Cornell University, Ithaca, NY, ⁶Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ⁷Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA), the most common chronic rheumatic disease occurring in childhood, is an important cause of disability. Despite the persistence of disease…
Abstract Number: 54 • 2017 Pediatric Rheumatology Symposium
Treatment and 1-year outcomes of an inception cohort of Australian children with JIA
Georgina Tiller¹, Jo Buckle², Jane Munro³, Angela Cox², Peter Gowdie², Roger Allen⁴ and Jonathan Akikusa^5,6, ¹Rheumatology, Royal Childrens Hospital, Parkville, Australia, ²Rheumatology, Royal Children's Hospital, Melbourne, Australia, ³Rheumatology, Royal Children's Hospital, Parkville, Australia, ⁴Paediatric Consulting Centre, Royal Childrens Hospital, Melbourne, VIC, Australia, ⁵Arthritis and Rheumatology Research, Murdoch Childrens Research Institute, Parkville, Australia, ⁶3 West Clinical Offices, Royal, Royal Children's Hospital, Melbourne, Australia
Background/Purpose: Recent studies have provided insight into the short and intermediate term outcomes of cohorts of children with JIA managed with contemporary treatments in North…
Abstract Number: 396 • 2016 ACR/ARHP Annual Meeting
Performance of Disease Activity Measures in Juvenile Spondyloarthritis in a Placebo Controlled Trial with Infliximab
Sofia Ramiro¹, Julio Casasola², Désirée van der Heijde³, RBM Landewé⁴ and Rubén Burgos-Vargas⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Hospital General de Mexico, Mexico, Mexico, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico
Background/Purpose: Several outcome measures in trials with juvenile-onset spondyloarthritis (Jo-SpA) have been borrowed from trials in juvenile idiopathic arthritis and from adult spondyloarthritis, but a…
Abstract Number: 404 • 2016 ACR/ARHP Annual Meeting
Disease Activity and Damage in Juvenile Idiopathic Arthritis: Comparison Between “Methotrexate” and “Biologic” Era
Gabriella Giancane¹, Valentina Muratore², Valentina Marzetti³, Neus Quilis⁴, Belen Serrano⁵, Alessandra Alongi⁵, Adele Civino⁶, Lorenzo Quartulli⁷, Alessandro Consolaro², Alberto Martini² and Angelo Ravelli², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³IRCCS G. Gaslini, Genoa, Italy, ⁴Pediatria II Reumatologia, IRCCS G. Gaslini, Genoa, Italy, ⁵Pediatria II, IRCCS G. Gaslini, Genoa, Italy, ⁶Azienda Ospedaliera Card G Panico, Tricase, Italy, ⁷UOC Pediatria - AO "Card.G.Panico", Tricase, Italy
Background/Purpose: The introduction of biologic agents at the beginning of the 2000s has represented a major advance in the management of juvenile idiopathic arthritis (JIA).…
Abstract Number: 405 • 2016 ACR/ARHP Annual Meeting
Patterns of Medication Use in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Sarah Ringold¹, Yukiko Kimura², Laura E. Schanberg³, Marc D. Natter⁴, Fenglong Xie⁵, Norman Ilowite⁶, Jason Jones⁷, Kelly Mieszkalski⁸, Timothy Beukelman⁹ and for the CARRA Registry Investigators, ¹Pediatrics, Seattle Children's Hospital, Seattle, WA, ²Hackensack University Medical Center, Hackensack, NJ, ³Pediatrics, Duke Medical Center, Durham, NC, ⁴Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁷Childhood Arthritis and Research Rheumatology Alliance (CARRA), Durham, NC, ⁸Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, ⁹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multicenter, prospective observational study collecting data from children with rheumatic diseases in order…
Abstract Number: 3050 • 2016 ACR/ARHP Annual Meeting
Post-Partum Complications and Depression in New Mothers with Juvenile Arthritis
Debbie Ehrmann Feldman¹, Evelyne Vinet², Marie-Pierre Sylvestre³, Elizabeth Hazel^4,5, Ciarán M. Duffy⁶, Anick Bérard⁷, Garbis Meshefedjian⁸ and Sasha Bernatsky⁹, ¹School of Rehabilitation, Université de Montréal, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Université de Montréal, Montreal, QC, Canada, ⁴Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁵Rheumatology, McGill University Health Centre, Pointe-Claire, QC, Canada, ⁶Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷Université de Montréal, Montréal, QC, Canada, ⁸Public Health Department of Montreal, Montreal, QC, Canada, ⁹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: There is little information regarding maternal post-partum complications in women with inflammatory arthritis conditions and none on persons with juvenile arthritis. Our objective was…
Abstract Number: 2026 • 2015 ACR/ARHP Annual Meeting
A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis
Cory M. Resnick¹, Pouya Vakilian², Micheal Breen³, David Zurakowski⁴, Zachary S. Peacock⁵ and Leonard B. Kaban⁵, ¹Plastics and Oral Surgery, Boston Children's Hospital, boston, MA, ²Harvard School of Dental Medicine, Boston, MA, ³Radiology, Boston Children's Hospital, Boston, MA, ⁴Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ⁵Oral and Maxillofacial Surgery, Massachusetts General Hospital, Boston, MA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) commonly affects the temporomandibular joints (TMJ) and may cause growth disturbance, functional limitation and facial deformity. Early diagnosis and management…
Abstract Number: 2440 • 2015 ACR/ARHP Annual Meeting
Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Roberta Berard³, Natalie Shiff⁴, Roman Jurencak⁵, Susanne Benseler⁶, Lori B. Tucker⁷ and ReACCh-Out Investigators, ¹Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Children's Hospital of Western Ontario, London, ON, Canada, ⁴Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ⁷Rheumatology, BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements,…
Abstract Number: 2580 • 2015 ACR/ARHP Annual Meeting
Age-Related Differences in Collagen-Induced Arthritis: Clinical, Imaging and Biological Characteristics in Juvenile Compared to Adult Animals
Tracy Wilson-Gerwing¹, Arash Panahifar², David M.L. Cooper² and Alan M. Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Anatomy and Cell Biology, University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: Arthritis is among the most common chronic diseases in both children and adults. Joint inflammation is a feature in both age groups but there…
Abstract Number: 3180 • 2015 ACR/ARHP Annual Meeting
Mesenchymal Stromal Cell Treatment in Juvenile Idiopathic Arthritis: A Pilot Study
Joost Swart¹, Nico Wulffraat², Berent J. Prakken³, Ineke Slaper-Cortenbach⁴ and Caroline Lindemans⁵, ¹PO Box 85090, UMC Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center, Utrecht, Netherlands, ⁴Cell Therapy Facility, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a frequent childhood disease with a prevalence of 1 per 1000 children. The introduction of the biological agents including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].